Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health
Antoine Vanier(Université de Tours), Dominique Le Guludec(Fondazione Toscana Gabriele Monasterio), Rodolphe Thiébaut(Université de Bordeaux), Bruno Falissard(Inserm), Lise Alter(Institute of Technology Assessment), Corinne Alberti(Inserm), Dominique Costagliola(Inserm), Jérôme Lambert(Délégation Paris 7), Patrick Semenzato(Institute of Technology Assessment), Sylvie Chevret(Saint Louis University Hospital), Clara Locher(Université Paris-Sud), Michel Cucherat(Lyon 1 Université), Sophie Kelley(Institute of Technology Assessment), Raphaël Porcher(Hotel Dieu Hospital), Judith Fernandez(Institute of Technology Assessment), Sarah Zohar(Inserm), Florian Naudet(Inserm), François Gueyffier(Centre National de la Recherche Scientifique), Étienne Lengliné(Assistance Publique – Hôpitaux de Paris), Pierre Cochat(Karolinska Institutet), Muriel Vray(Institut Pasteur)
Cited by 52
Related Papers
Using and Reporting the Delphi Method for Selecting Healthcare Quality Indicators: A Systematic Review
|PLoS ONE|2011|2k
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
|AIDS|2003|987
Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study
|Intensive Care Medicine|2001|984
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777